ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study September 19, 2020
Sacituzumab govitecan in previously treated HR+/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial September 14, 2020 0